TSX Growth Stocks With Up To 86% Insider Driven Earnings Expansion

As the Federal Reserve maintains its interest rates and economic growth shows signs of cooling, Canadian markets are navigating a landscape marked by rising inflation and potential rate cuts from the Bank of Canada. In this environment, stocks with high insider ownership can be appealing as they often signal strong confidence from those closest to the company, potentially aligning well with investor interests in times of economic uncertainty.

Top 10 Growth Companies With High Insider Ownership In Canada

Click here to see the full list of 36 stocks from our Fast Growing TSX Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Allied Gold (TSX:AAUC)

Simply Wall St Growth Rating: ★★★★★★

Overview: Allied Gold Corporation, along with its subsidiaries, is involved in the exploration and production of mineral deposits in Africa and has a market cap of CA$1.57 billion.

Operations: The company's revenue segments are not specified in the provided text.

Insider Ownership: 17.7%

Earnings Growth Forecast: 75.4% p.a.

Allied Gold is poised for growth, with revenue expected to outpace the Canadian market significantly. Despite recent shareholder dilution, the company trades well below its estimated fair value and has a strategic alliance with Ambrosia Investment Holding to enhance financial strength and growth. Allied's annual earnings are projected to grow robustly, supported by increased gold production and operational improvements at its Sadiola mine. Recent financial results show reduced net losses, indicating progress towards profitability.

• Navigate through the intricacies of Allied Gold with our comprehensive analyst estimates report here.
• According our valuation report, there's an indication that Allied Gold's share price might be on the cheaper side.

Africa Oil (TSX:AOI)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Africa Oil Corp. is an oil and gas exploration and production company operating in Nigeria, Namibia, South Africa, and Equatorial Guinea with a market cap of CA$922.08 million.

Operations: The company generates revenue through its operations in oil and gas exploration and production across Nigeria, Namibia, South Africa, and Equatorial Guinea.

Insider Ownership: 13%

Earnings Growth Forecast: 86.9% p.a.

Africa Oil exhibits potential for growth with revenue projected to expand rapidly, outpacing the Canadian market. Despite trading significantly below its estimated fair value, insider ownership remains substantial. Recent board restructuring and a new CFO may influence strategic direction. While the company faces challenges with unsustainable dividends and past net losses, production guidance suggests improvement. The firm’s involvement in promising offshore projects like Block 2913B could enhance future profitability prospects.

• Delve into the full analysis future growth report here for a deeper understanding of Africa Oil.
• Our expertly prepared valuation report Africa Oil implies its share price may be lower than expected.

Knight Therapeutics (TSX:GUD)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Knight Therapeutics Inc. is a specialty pharmaceutical company that acquires, licenses, markets, and commercializes pharmaceutical products in Canada and Latin America with a market cap of CA$602.28 million.

Operations: The company's revenue is primarily derived from its pharmaceuticals segment, which generated CA$371.30 million.

Insider Ownership: 22.7%

Earnings Growth Forecast: 38.2% p.a.

Knight Therapeutics is experiencing strong earnings growth, with profits forecast to increase significantly above the Canadian market average. Recent financial results show a turnaround from losses to profitability, and revenue for 2025 is expected between C$390 million and C$405 million. The company has launched Minjuvi® in Mexico, enhancing its oncology portfolio. Despite trading below its estimated fair value, Knight's strategic agreements in Latin America position it well for future growth opportunities in the pharmaceutical sector.

• Unlock comprehensive insights into our analysis of Knight Therapeutics stock in this growth report.
• Our valuation report unveils the possibility Knight Therapeutics' shares may be trading at a discount.

Make It Happen

• Get an in-depth perspective on all 36 Fast Growing TSX Companies With High Insider Ownership by using our screener here.
• Contemplating Other Strategies? Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com